샘플 요청 목록

 카트 문의
시장보고서
상품코드
1795323

세계의 황산 퀴니딘 시장

Quinidine Sulfate
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 175 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

황산 퀴니딘 세계 시장은 2030년까지 13억 달러에 달할 전망

2024년에 11억 달러로 추정되는 황산 퀴니딘 세계 시장은 분석 기간인 2024-2030년에 CAGR 2.9%로 성장하여 2030년에는 13억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 말라리아는 CAGR 2.2%를 기록하며 분석 기간 종료시에는 7억 3,870만 달러에 달할 것으로 예측됩니다. 부정맥 부문의 성장률은 분석 기간 동안 CAGR 4.1%로 추정됩니다.

미국 시장은 3억 380만 달러로 추정, 중국은 CAGR 5.4%로 성장 예측

미국의 황산 퀴니딘 시장은 2024년에 3억 380만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 5.4%로 2030년까지 2억 5,650만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 1.2%와 2.2%로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%로 성장할 것으로 예측됩니다.

세계의 황산 퀴니딘 시장 - 주요 동향과 촉진요인 정리

최신 심혈관 치료에서 황산 퀴니딘의 역할은 무엇인가?

퀴니딘 황산염은 주로 심방 부정맥과 심실 부정맥 치료에 사용되는 중요한 항부정맥제로서 오랫동안 그 위치를 차지해 왔습니다. 키니딘은 키나노나무 껍질에서 추출한 성분으로 심장의 전기 전도를 지연시켜 심장 리듬을 안정시키고 빈맥성 부정맥의 재발을 예방합니다. 임상 현장에서는 생체이용률과 약동학이 우수하기 때문에 황산염 형태로 경구 투여하는 것이 가장 일반적입니다. 새로운 항부정맥제의 출현으로 그 사용이 감소하고 있지만, 특히 현대의 대체 약물에 대한 불내성이나 내성을 보이는 환자에게는 여전히 필수적인 약물입니다. 또한, 부르가다 증후군과 일부 QT 단축 증후군에 대한 효과로 인해 그 사용이 재검토되고 있습니다.

의료진은 특히 심방세동 환자의 장기적인 리듬 유지 요법을 위해 황산퀴니딘을 신중하게 점진적으로 처방하는 경우가 많습니다. 또한, 다른 퀴닌 유도체가 효과가 없는 내성 말라리아 원충의 치료에도 사용됩니다. 이러한 이중적 사용법이 WHO의 필수 의약품 모델 목록에 등재된 배경에는 순환기 질환과 열대성 질환의 약물 치료에서 키니네의 지속적인 중요성이 있습니다. 현재 의학 문헌에서는 정밀 기반 치료 프로토콜이 소아 심장병과 희귀 유전성 부정맥에서 그 가치를 강조하고 있습니다.

시장 타당성을 뒷받침하는 주요 용도 및 최종 용도 동향은?

세계 퀴니딘 황산염 시장은 주로 병원, 심장 전문 의료 센터 및 연구 기관에서의 응용 분야에 의해 주도되고 있습니다. 이 화합물은 경구제와 주사제로 공급되고 있으며, 외래환자용으로는 경구용 황산염 제제가 주류를 이루고 있습니다. 부정맥 관리, 특히 여러 합병증을 앓고 있는 고령 환자들에 대한 관심이 높아지면서 퀴니딘 기반 요법에 대한 수요는 계속 증가할 것으로 예상됩니다. 또한, 심방세동 및 선천성 증후군에 대한 최적의 약물 경로를 확인하기 위한 약리유전체학의 활용이 증가함에 따라 기존의 항부정맥제, 특히 퀴니딘과 같이 안전성 프로파일이 잘 입증된 항부정맥제에 대한 관심이 활성화되고 있습니다.

최종 사용의 역동성 측면에서 이 화합물은 학술 연구 및 약물 재포지셔닝 이니셔티브에서 새로운 수요를 목격하고 있습니다. ALS(근위축성측색경화증)나 간질과 같은 신경근육 질환에서 나트륨 채널을 고유한 방식으로 조절하는 황산 퀴니딘의 재배치가 연구되고 있습니다. 특히 말의 심장 질환에 대한 적용이 검토되고 있습니다. 또한, 저개발 지역의 약제 내성 말라리아 균주를 대상으로 하는 세계 보건 이니셔티브는 공중 보건 채널을 통한 정부 조달을 촉진하여 황산 퀴니딘 시장에 일반적으로 알려진 것보다 더 넓은 지리적, 치료적 범위를 부여하고 있습니다.

규제와 의약품 공급망은 시장 확대를 어떻게 형성하고 있는가?

황산 퀴니딘을 관리하는 규제 상황은 엄격한 품질, 용량 및 약물감시 기준이 특징입니다. 북미와 유럽에서는 QT 연장 및 Torsades de Pointes의 위험이 있기 때문에 그 사용이 엄격하게 통제되고 있으며, 종종 심장 모니터링이 필요합니다. 그러나 이러한 규제로 인해 특히 선천성 부정맥 발생률이 높은 지역이나 대체요법이 경제적으로 실행 불가능한 지역에서 그 유용성이 감소되는 것은 아닙니다. 인도, 중국, 동유럽의 제네릭 의약품 제조업체는 세계 공급망에 기여하고, 신흥 시장에서 황산 퀴니딘을 쉽게 구할 수 있도록 하며, 국제 원조 및 보건 프로그램을 지원하고 있습니다.

공급망 관점에서 볼 때, 한정된 원료의약품(API) 공급업체에 의존하고 있기 때문에 시장은 정기적인 도전에 직면해 있습니다. 천연 자원에서 퀴니딘을 추출하는 것은 복잡하고, 합성 생산은 여전히 비용 집약적입니다. 이러한 요인들이 최근 가격 변동에 영향을 미치고 있습니다. 이러한 상황에도 불구하고 브라질, 인도네시아, 남아프리카공화국 등의 국가에서는 정부 지원의 필수의약품 프로그램이나 희귀질환 상환제도 편입으로 인해 유통 채널이 활발하게 유지되고 있습니다. 또한, NGO와 제약사와의 제휴를 통해 상업화가 진행되지 않은, 임상 의존도가 높은 지역 시장에도 황산키니딘의 발자취를 넓혀가고 있습니다.

황산 퀴니딘 시장의 성장 원동력은 무엇인가?

황산퀴니딘 시장의 성장 원동력은 몇 가지 요인에 기인하며, 특히 유전적으로 유발되는 부정맥 및 희귀 심장 증후군 관리에 대한 임상적 관심이 다시금 높아지고 있습니다. 특히 고령화 사회에서 심방세동의 증가는 기존의 베타차단제나 칼슘길항제 이외의 다양한 약리학적 대안에 대한 수요를 창출하고 있습니다. 또한, 맞춤의료가 다시금 강조되면서 황산키니딘은 환자 개개인의 프로파일과 효능을 나타내는 유전자 마커에 따라 선택적으로 재도입되고 있습니다.

특히 연구자들이 나트륨 채널 관련 신경 질환 치료에 대한 적응증 외의 가능성을 발견함에 따라 약물 재사용에 대한 노력이 시장 성장을 더욱 촉진하고 있습니다. 또한, 특정 지역에서는 약제 내성 말라리아 퇴치에도 중요한 역할을 하고 있으며, 여전히 효과적이고 필수적인 2차 치료제로서 시장을 뒷받침하고 있습니다. 또한, 특정 공공 의료 시스템에서 새로운 항부정맥제보다 황산 퀴니딘이 비용면에서 더 유리하기 때문에 그 사용은 계속 강화되고 있습니다. 학술 시험 및 기관 연구들이 사용 사례의 확대를 모색함에 따라, 황산 퀴니딘 세계 시장은 향후 10년간 치료 분야 및 지역 부문에 관계없이 안정적인 성장세를 유지할 것으로 예상됩니다.

부문

질환 유형(말라리아, 부정맥, 기타 질환)

조사 대상 기업 사례

  • ALLURE REMEDIES PVT. LTD.
  • Aurobindo Pharma
  • Bennet Pharmaceuticals Ltd
  • Biophore India Pharmaceuticals Pvt. Ltd
  • Buchler GmbH
  • Cipla Ltd
  • Dr.Reddy's Laboratories Ltd
  • Intas Pharmaceuticals
  • Ipca Laboratories Ltd
  • Lark Laboratories India Ltd
  • Merck & Co., Inc.
  • Merck KGaA
  • Mylan N.V.(Viatrus/Mylan)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Skymax Laboratories
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유의 SLM을 조회하는 일반적인 규범을 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가가 선별한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.08.28

Global Quinidine Sulfate Market to Reach US$1.3 Billion by 2030

The global market for Quinidine Sulfate estimated at US$1.1 Billion in the year 2024, is expected to reach US$1.3 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Malaria, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$738.7 Million by the end of the analysis period. Growth in the Arrhythmias segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$303.8 Million While China is Forecast to Grow at 5.4% CAGR

The Quinidine Sulfate market in the U.S. is estimated at US$303.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$256.5 Million by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Quinidine Sulfate Market - Key Trends & Drivers Summarized

What Role Does Quinidine Sulfate Play in Modern Cardiovascular Therapies?

Quinidine sulfate has long held its position as a key antiarrhythmic agent, primarily used in the treatment of atrial and ventricular arrhythmias. Derived from the cinchona bark, quinidine works by slowing electrical conduction in the heart, stabilizing rhythm, and preventing recurrent episodes of tachyarrhythmia. In clinical settings, it is most commonly administered orally in sulfate form due to its superior bioavailability and pharmacokinetics. Although its use has declined with the advent of newer antiarrhythmic drugs, it remains an essential agent for niche applications, particularly in patients who demonstrate intolerance or resistance to contemporary alternatives. Its use is also being revisited due to its efficacy in treating Brugada syndrome and certain forms of short QT syndrome.

Healthcare practitioners often prescribe quinidine sulfate in carefully titrated doses, especially for long-term rhythm maintenance therapy in atrial fibrillation patients. The drug is also indicated in the management of malaria caused by Plasmodium falciparum in resistant cases, where other quinine derivatives fail. This duality of use supports its inclusion on the WHO Model List of Essential Medicines, indicating its continued relevance in both cardiovascular and tropical disease pharmacotherapy. Current medical literature highlights its value in pediatric cardiology and rare genetic arrhythmias where precision-based treatment protocols are evolving.

What Are the Key Applications and End-Use Trends Supporting Its Market Relevance?

The global quinidine sulfate market is majorly driven by applications in hospitals, specialty cardiac care centers, and research institutions. The compound is supplied in oral and injectable formats, with the oral sulfate form dominating the outpatient segment. With increasing focus on arrhythmia management, particularly in geriatric patients with multiple comorbidities, the demand for quinidine-based regimens remains relevant. Furthermore, the rising use of pharmacogenomics to identify optimal drug pathways for atrial fibrillation and congenital syndromes has revitalized interest in older antiarrhythmic compounds, especially those with a well-documented safety profile like quinidine.

In terms of end-use dynamics, the compound is witnessing renewed demand in academic research and drug repositioning initiatives. Research efforts are examining the repositioning of quinidine sulfate for neuromuscular diseases such as ALS (Amyotrophic Lateral Sclerosis) and epilepsy, where it modulates sodium channels in unique ways. Veterinary applications are also under investigation, particularly for equine cardiac conditions. Additionally, global health initiatives targeting drug-resistant malaria strains in underdeveloped regions are driving government procurements through public health channels, giving the quinidine sulfate market a broader geographical and therapeutic reach than typically acknowledged.

How Are Regulations and Drug Supply Chains Shaping Market Expansion?

The regulatory landscape governing quinidine sulfate is characterized by stringent quality, dosage, and pharmacovigilance standards. In North America and Europe, its use is tightly controlled, often requiring cardiac monitoring due to the risk of QT prolongation and torsades de pointes. However, these regulations have not dampened its utility, particularly in regions with high incidence of congenital arrhythmias or where alternative therapies are economically unfeasible. Generic manufacturers in India, China, and Eastern Europe have contributed to the global supply chain, making quinidine sulfate accessible in emerging markets while also supporting international aid and health programs.

From a supply chain perspective, the market faces periodic challenges due to reliance on limited active pharmaceutical ingredient (API) suppliers. The extraction of quinidine from natural sources is complex, and synthetic production remains cost-intensive. These factors have contributed to price volatility in recent years. Despite this, government-backed essential medicine programs and inclusion in rare disease reimbursement frameworks in countries like Brazil, Indonesia, and South Africa are keeping the distribution channels active. Partnerships between NGOs and pharmaceutical suppliers are also expanding the footprint of quinidine sulfate into less commercialized, yet clinically dependent, regional markets.

What Is Driving the Growth of the Quinidine Sulfate Market?

The growth in the quinidine sulfate market is driven by several factors, most notably the resurgence in clinical interest for managing genetically triggered arrhythmias and rare cardiac syndromes. Rising incidences of atrial fibrillation globally, especially among aging populations, have created a parallel demand for diverse pharmacologic options beyond contemporary beta-blockers and calcium channel blockers. The renewed emphasis on personalized medicine is also leading to selective re-adoption of quinidine sulfate based on individual patient profiles and genetic markers that favor its efficacy.

Drug repurposing initiatives further support market growth, especially as researchers uncover its off-label potential in treating sodium-channel related neurological conditions. The market is additionally supported by its role in combating drug-resistant malaria in specific geographies, where it remains an effective and essential second-line treatment. Moreover, the cost advantage of quinidine sulfate over newer antiarrhythmic agents in certain public healthcare systems continues to reinforce its usage. With academic trials and institutional research exploring expanded use cases, the global market for quinidine sulfate is expected to maintain steady growth across therapeutic and geographic segments over the coming decade.

SCOPE OF STUDY:

The report analyzes the Quinidine Sulfate market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Malaria, Arrhythmias, Other Diseases)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • ALLURE REMEDIES PVT. LTD.
  • Aurobindo Pharma
  • Bennet Pharmaceuticals Ltd
  • Biophore India Pharmaceuticals Pvt. Ltd
  • Buchler GmbH
  • Cipla Ltd
  • Dr.?Reddy's Laboratories Ltd
  • Intas Pharmaceuticals
  • Ipca Laboratories Ltd
  • Lark Laboratories India Ltd
  • Merck & Co., Inc.
  • Merck KGaA
  • Mylan N.V. (Viatrus/Mylan)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Skymax Laboratories
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Quinidine Sulfate - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Atrial Fibrillation and Cardiac Arrhythmias Drives Demand for Antiarrhythmic Drugs
    • Innovation in Extended-Release Formulations Strengthens Treatment Adherence
    • Growth in Rare Disease Treatment Protocols Throws the Spotlight on Quinidine's Broader Applications
    • Regulatory Reapprovals for Repurposed Molecules Promote Quinidine Use in Orphan Indications
    • Development of Digital Cardiology Platforms Enhances Drug Monitoring Capabilities
    • Increasing Availability of Compounded Quinidine Formulations Boosts Hospital-Based Prescriptions
    • Partnerships With Cardiologists Strengthen Protocol-Based Dosing Adoption
    • Growing Research on Genetic Markers in Drug Metabolism Supports Personalized Dosage Regimens
    • Focus on Drug-Drug Interaction Risk Management Promotes Safer Combination Therapies
    • Expansion of Quinidine Application in Neurological Disorders Broadens Therapeutic Potential
    • Regulatory Guidance on Narrow Therapeutic Index Drugs Drives Monitoring Standards
    • Innovation in Microdose and Pediatric Formulations Supports Specialty Market Penetration
    • Rising Emphasis on Labeling Accuracy and GMP Compliance Fuels Manufacturing Modernization
    • Collaboration With Pharmacovigilance Networks Improves Long-Term Safety Profiling
    • Growth in Availability of Online Pharmacies and Specialty Drug Distributors Enhances Market Reach
    • Entry Into Global Licensing Agreements Strengthens Regional Access Strategies
    • Increasing Interest in Drug Repositioning Accelerates Investment in Quinidine Research
    • Support for Cardiology Clinics and Hospital Networks Boosts Direct Engagement
    • Emergence of Drug Supply Shortage Mitigation Programs Promotes Production Scalability
    • Expansion of Clinical Trial Evidence Base Elevates Prescriber Confidence in Quinidine Use
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Quinidine Sulfate Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Quinidine Sulfate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Malaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Malaria by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Malaria by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Arrhythmias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Arrhythmias by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Arrhythmias by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • JAPAN
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • CHINA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: China 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • EUROPE
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Quinidine Sulfate by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • FRANCE
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: France 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • GERMANY
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Quinidine Sulfate by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • INDIA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: India 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Quinidine Sulfate by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Quinidine Sulfate by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Quinidine Sulfate by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030
  • AFRICA
    • Quinidine Sulfate Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Quinidine Sulfate by Disease Type - Malaria, Arrhythmias and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Quinidine Sulfate by Disease Type - Percentage Breakdown of Value Sales for Malaria, Arrhythmias and Other Diseases for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제